Methazolamide

Add Info

Methazolamide Recall

Get an alert when a recall is issued.

Ask a Question

Questions & Answers

Add Info

Side Effects & Adverse Reactions

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration.

If hypersensitivity or other serious reactions occur, the use of this drug should be discontinued.

Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma, and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.

Add Info

Legal Issues

There is currently no legal information available for this drug.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

Methazolamide Tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

Methazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone. The chemical name for methazolamide is: N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazo1-2(3H)-ylidene]-acetamide and it has the following structural formula:

Molecular Formula: C5H8N4O3S2 Molecular Weight: 236.26

Each tablet, for oral administration, contains 25 mg or 50 mg of methazolamide USP. In addition, each tablet contains the following inactive ingredients: dibasic calcium phosphate dihydrate, glyceryl behenate, povidone, pregelatinized starch, and sodium starch glycolate.

Sources

Methazolamide Manufacturers

Ani Pharmaceuticals, Inc.

Methazolamide | Ani Pharmaceuticals, Inc.

The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Paddock Laboratories, Llc

Methazolamide | Paddock Laboratories, Llc

The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Fera Pharmaceuticals

Methazolamide | Fera Pharmaceuticals

The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Physicians Total Care, Inc.

Methazolamide | Physicians Total Care, Inc.

The effective therapeutic dose administered varies from 50 mg to 100 mg 2 or 3 times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Sandoz Inc

Methazolamide | Sandoz Inc

The effective therapeutic dose administered varies from 50 mg to 100 mg 2 or 3 times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Effcon Laboratories, Inc.

Methazolamide | Effcon Laboratories, Inc.

The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall
Carilion Materials Management

Methazolamide | Carilion Materials Management

The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.

No Recall